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Abstract
Treatment of blood loss with plasma expanders lowers blood viscosity, increasing cardiac output. However, increased flow
velocity by conventional plasma expanders does not compensate for decreased viscosity in maintaining vessel wall shear
stress (WSS), decreasing endothelial nitric oxide (NO) production. A new type of plasma expander using polyethylene glycol
conjugate albumin (PEG-Alb) causes supra-perfusion when used in extreme hemodilution and is effective in treating
hemorrhagic shock, although it is minimally viscogenic. An acute 40% hemodilution/exchange-transfusion protocol was
used to compare 4% PEG-Alb to Ringer’s lactate, Dextran 70 kDa and 6% Hetastarch (670 kDa) in unanesthetized CD-1 mice.
Serum cytokine analysis showed that PEG-Alb elevates monocyte chemotactic protein-1 (MCP-1), a member of a small
inducible gene family, as well as expression of MIP-1a, and MIP-2. MCP-1 is specific to increased WSS. Given the direct link
between increased WSS and production of NO, the beneficial resuscitation effects due to PEG-Alb plasma expansion appear
to be due to increased WSS through increased perfusion and blood flow rather than blood viscosity.
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Introduction
Plasma expanders are used to remedy the volume component of
blood loss until blood transfusion becomes necessary for the
maintenance of oxygen carrying capacity. Both colloidal and
crystalloid based solutions are used for this purpose. Their
application dilutes blood, lowering its viscosity and increasing
cardiac output, and therefore, blood flow. Within limits, this effect
maintains oxygen delivery capacity as fewer red blood cells (RBCs)
circulate more rapidly maintaining RBC flux. However, increased
flow velocity does not compensate for the decreased blood viscosity
in maintaining vessel wall shear stress (WSS). As a consequence
production of nitric oxide (NO) by the vessel wall is diminished [1]
causing vasoconstriction, which partially negates the increase in
flow due to lower blood viscosity.
In contrast to presently available passive plasma expanders,
a new approach to volume expansion is based on active plasma
expanders [2]. These fluids increase plasma viscosity in
hemodilution maintaining and increasing WSS in the microcir-
culation, promoting the release of NO, causing vasodilatation.
This mechanism in combination of the lower blood viscosity
due to hemodilution significantly increases cardiac output
causing a state of supra-perfusion. Furthermore, this combina-
tion of effects facilitates transmission of central blood pressure to
the microcirculation [3], maintaining functional capillary den-
sity, a parameter shown to improve survival during blood losses
[4,5].
Conjugation of human serum albumin (HSA) with poly-
ethylene glycol (PEG) [6,7] yields the colloid PEG-Albumin
(PEG-Alb) that has the same supra-perfusion properties as
viscogenic plasma expanders, such as alginate or dextran
500 kDa, however, Extension Arm Facilitated (EAF) PEG-Alb
is significantly less viscous. PEGylation confers to albumin
several desirable plasma expanding properties. It increases the
molecular dimensions, i.e., hydrodynamic volume six to eight
times more efficiently than a comparable mass of protein [8]
and lowers the biological reactivity to colloids, increases plasma
half-life, lowers immunoreactivity, and it appears to virtually
eliminate thrombogeneicity. As a consequence PEG-Alb has
consistently yielded better resuscitation outcomes when com-
pared to other similar plasma expanders in experimental models
of extreme hemodilution [7], hemorrhagic shock [6,9], and
endotoxemia [10].
Maintenance of high levels of perfusion found with PEG-Alb
resuscitation cannot be solely attributed to its viscogenic
properties contributing to increased WSS, since it is minimally
viscogenic [7] once diluted in blood. Increased WSS could be
due to increased flow, an effect that probably differs between
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conventional microcirculatory studies. Other mechanisms pro-
posed are direct physical interactions of the PEG-shell of PEG-
Alb with the endothelium, activation of the endothelium derived
vasodilator response [11] and PEG-Alb’s enhanced capacity to
transport NO as nitroso thiols [12]. However, experimental
observations and molecular characteristics do not evidence these
effects nor do they explain the superiority of PEG-Alb.
In our present study we analyze the differences in cytokine
expression following in vivo exposure to plasma expanders to
determine if PEG-Alb effects are related to the WSS/NO
mechanism. The PEG-Alb used in this study is generated by
a new approach to the PEGylation of proteins termed Extension
Arm Facilitated (EAF) PEGylation. This process engineers a zone
of extension arms, nearly 1 nm in thickness, between the outer
PEG-shell and the protein core. It has been suggested that the
intermediary zone of extension arms functions as a shock
absorber that maximizes shielding of the protein core from
macro-environmental effects, while minimizing the structural
perturbations of the protein core from PEG protein interactions
[5,13]. We compare cytokine expression due to 4% EAF PEG-
Alb application with the effects of plasma expanders that do not
show the supra-perfusion effect using an acute hemodilution/
exchange-transfusion (AHET) experimental protocol. We prin-
cipally focus on monocyte chemotactic protein-1 (MCP-1),
which is produced by the endothelium when WSS increases
[14,15,16].
Results
Preliminary investigations (n=1 per plasma expander, data not
included) were completed in individual animals following a 10%
top load-hypervolemic infusion prior to AHET investigations.
These data were used to assess the variation and timing in cytokine
production among the plasma expanders assessed prior to the
AHET investigation.
During the 40% AHET experimental protocol animals were
randomly assigned to 1 of 2 observation endpoints, 0.5 or 2 hrs
following the infusion of individual plasma expanders: Ringer’s
Lactate (RL; Baxter Healthcare Corporation Deerfield, IL),
Dextran (Dex; 70 kDa molecular weight; B. Braun Medical,
Inc., Irvine, CA), 6% Hetastarch (6Ht; 670 kDa average
molecular weight; Hospira, Inc., Lake Forest, IL), or 4% EAF
PEG-Alb (developed at Albert Einstein College of Medicine,
Bronx, NY).
Hierarchical clustering analysis was applied to AHET datasets
(n=2 per plasma expander/time point). The variability between
each of the two AHET samples analyzed according to plasma
expander and observation endpoint ranged from 0.1 to 65.9%.
However, the variability between AHET samples, according to
MCP-1 and the macrophage inflammatory proteins (MIP), MIP-
1a and MIP-2, amongst the plasma expanders only ranged from
6.1 to 6.9%.
Cytokine Analysis
Hemodilution with 4% EAF PEG-Alb increased the concen-
tration of all cytokines (Eotaxin, G-CSF, IL-10, IL-12 (p70), IL-13,
IL-1a, IL-6, IP-10, KC, LIX, MCP-1, MIG, MIP-1a, MIP-1b,
MIP-2, RANTES, and TNF-a) 0.5 and/or 2 hr post exchange,
compared to control animals (Figure 1). The level of production of
MCP-1, MIP-1a, and MIP-2, was highest in animals hemodiluted
with 4% EAF PEG-Alb, 2 hr following exchange transfusion
(Figure 2).
Blood Viscosities
Blood viscosity of 40% hemodiluted blood for each plasma
expander group was: Hetastarch 3.1 cP, Ringer’s Lactate 2.1 cP,
Dextran 70 3.8 cP and 4% EAF PEG-Alb 3.1 cP.
Discussion
The principal result of this study is that 2 hr after 40%
exchange transfusion in CD-1 mice 4% EAF PEG-Alb uniquely
increased MCP-1, MIP-1a, and MIP-2 expression by comparison
to Ringer’s Lactate, Dextran70, and 6% Hetastarch.
Figure 1. Acute hemodilution/exchange transfusion cytokines
Heat Map. Expression levels of individual cytokines corresponding to
the K and 2 hr post 40% exchange transfusion of the plasma
expanders: RL, Ringer’s Lactate; Dex, Dextran 70 kDa; 6Ht, 6%
Hetastarch; PEG, 4% EAF PEG-Alb. Cytokine post infusion expression
levels were normalized to control levels. 1 signifies that there was no
change relative to control. The remainder colors bracket multiples of
control concentration. Specific values for the only cytokines to have
enhanced expression due to one plasma expander 2 hr post infusion
are: MCP-1, 106control; MIP-1a,1 4 6control; and, MIP-2, 366control.
doi:10.1371/journal.pone.0039111.g001
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augmentation in endothelial cell culture investigations
[14,16,17,18] that peaks 1.5 hr following the initial rise in shear
stress [14], a time course for gene up-regulation similar to that
found in our present study. Therefore, our result evidences that
4% EAF PEG-Alb plasma expansion significantly increases WSS
as compared to the other plasma expanders of comparable
viscosity. This might explain the supra-perfusion caused by EAF-
PEG-Alb since measurement of NO concentration in the
microvascular vessel wall with micro-electrodes show that in-
creased WSS due to high viscosity plasma expander hemodilution
significantly increases NO concentration, leading to the vasodila-
tor effects necessary for increasing perfusion [1].
MCP-1, MIP-1a, and MIP-2 are generally viewed as proin-
flammatory and are associated with vascular trauma and
cardiovascular related diseases that present leukocyte activation
followed by vascular transmigration [19,20]. However, these
phenomena are not present or evident in the current investiga-
tions. The short circulation half-life (,24 hr) of the plasma
expanders, and the association of MCP-1 with angiogenic
molecular pathways [21,22], although a process not specifically
related to plasma expansion, further supports the conclusion that
the significant up-regulation of MCP-1 by 4% EAF PEG-Alb is
caused by increased WSS in the circulation, an effect absent when
using conventional plasma expanders. Notably, RANTES, a cyto-
kine also associated with the increase in WSS [23] was only
Figure 2. Acute hemodilution/exchange transfusion. Expression of (A) MCP-1, (B) MIP-1a, and (C) MIP-2 chemokines, 0.5 and 2 hrs post
exchange transfusion of individual plasma expanders, 6% Hetastarch, Ringer’s Lactate, Dextran 70, or EAF PEG-Alb. EAF PEG-Alb was the only plasma
expander to cause expression to exceed control levels at either the 0.5 or 2 hr assessment point following hemodilution.
doi:10.1371/journal.pone.0039111.g002
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(1.66control) and 4% EAF PEG-Alb (1.86control).
Additionally, the advantageous effects of MIP-1a and MIP-2
concern their stimulatory influence on hematopoietic progenitor
(HPC) and stem cell (HSC) mobilization from the bone marrow
to peripheral blood, [24,25,26] to be used for autologous or
allogeneic transplantation. However, recent investigations have
built on the assumption that HSCs have the capacity, as with
other tissue derived stems cells, to contribute to the regeneration
of non-native tissue [27]. Findings reported by Grant M. et al.
indicated that HSCs and HPCs can in fact be a major source of
endothelial cells used for ischemia induced neovascularization
[28]. Previous experimental protocol time scales [6,7,10] do not
allow for the significant benefits reported for 4% EAF PEG-Alb
to be related to neovascularization. However, HSCs and HPCs
plasticity allowing their incorporation into the surrounding
tissue, as well as the endothelium is believed to initiate tissue
preservation and/or regeneration signaling, a driving factor in
the conservation and/or reestablishment of tissue perfusion
following injury. Reportedly, stimulation of HSC and HPC
mobilization following MIP-1a and MIP-2 is rapid and dose
dependent [26,29]. Thus, 4% EAF PEG-Alb stimulated
mobilization of HSC and HPC is possible within previous
experimental protocol time frames [6,7,10].
EAF PEG-Alb also increases the concentration the hematopoi-
etic cytokines G-CSF (496control) and IL-6 (3536control) 2 hr
after exchange transfusion. These cytokines function as hormones
that regulate blood cell production and are used in the
management of anemia and neutropenia. This suggests that
EAF PEG-Alb signals hematopoiesis, an effect also evidenced to
a lesser extent by exchange transfusion with 6% Hetastarch,
driven by the reduction in oxygen carrying capacity due to
hemodilution.
The increase in cytokine expression following exchange trans-
fusion with each plasma expander may most likely be also in part
due to a general response of the organism to the alteration of blood
composition and the introduction of a foreign material into the
circulation. The increased expression of proinflammatory and
inflammatory cytokines IL1a, IL1b, IL-6, IL-10, IL12, IL13,
TNFa and Eotaxin by EAF PEG-Alb relative to the other plasma
expanders is probably also related to RL, Dextran 70 and
Hetarstarch being produced in GMP conditions for human use,
while EAF PEG-Alb was produced in clean laboratory conditions.
Cytokines should return to baseline levels within a time frame
commensurate with the half-life of plasma expanders, a question to
be addressed in further studies.
In conclusion, plasma expansion with 4% EAF PEG-Alb is
associated with the elevation of MCP-1, a chemokine specifically
related to increased shear stress on the endothelium, [14,16,17,18]
which increases NO production causing vasodilatation. Lowered
blood viscosity due to hemodilution in combination with the
increase in NO that should be the consequence of increased WSS
promotes vasodilatation and a condition of enhanced perfusion,
which maintains WSS and endows EAF PEG-Alb with highly
beneficial plasma expansion properties. Moreover, 4% EAF PEG-
Alb significantly increases expression of hemopoietic cytokines
potentially signaling the bone marrow to supplement the de-
ficiency of blood cells.
Materials and Methods
Ethics Statement
The Guide for the Care and Use of Laboratory Animals (US
National Research Council, 1996) was followed for animal
handling and provided care. The protocol was approved by the
University of California, San Diego Animal Subjects Committee
(Permit Number: S09221). All surgery was performed under
sodium pentobarbital anesthesia, and every effort was made to
minimize suffering.
Polyethylene Glycol Surface Decorated Human Serum
Albumin (PEG-albumin)
EAF PEGylation of albumin was carried out as described
previously [5]. Briefly, lyophilized preparations of albumin from
Sigma Aldrich were subjected to EAF PEGylation at a temperature
of 4uC and a protein concentration of 0.5 mM, using 10 mM
maleimidophenyl PEG 5K (custom synthesized), in the presence of
5 mM 2-IT. The hexaPEGylated albumin thus generated had
molecular weight 95–100 kDa and was then purified through
tangential flow filtration and concentrated to a 4 g% solution and
stored at 280uC.
Animal Model and Preparation
Investigations were performed in CD-1 mice (Charles River), 6
to 7 weeks of age, weighing 18–20 grams, using a simplified
version of the window chamber model used for microvascular
studies in unanesthetized animals. This model was used to support
the catheters and prevent the mice from damaging the catheters,
while maintaining them in place. Chamber and vascular
catheterization surgeries were performed under general anesthesia,
50 mg/kg i.p. injections, as described previously [30,31] with the
modification that the surgical exposure of the tissue and its
microcirculation was not implemented. Following chamber
implantation, animals were allowed a minimum 2 day recovery
period prior to catheterization. Animals were anesthetized for
carotid artery and jugular vein catheter implantation (poly-
ethylene-50), following chamber assessment ruling out the
presence of edema, bleeding, or signs of infection.
Inclusion Criteria
All surgical sites of investigated animals were free from signs of
edema or bleeding on the day of experimentation. Animals needed
also to fulfill baseline systemic parameter requirements: mean
arterial pressure (MAP) above 80 mmHg, heart rate (HR) above
320 beats/min, systemic hematocrit (Hct) above 40%, and arterial
oxygen tension above 50 mmHg.
Systemic Parameters
MAP and HR were monitored using a Biopac acquisition
system (MP 150; Biopac Systems, Inc., Santa Barbara, CA).
Systemic Hct was measured from arterial blood collected in
heparinized microcapillary tubes and centrifuged.
Experimental Groups
Preliminary investigations of plasma expanders were complet-
ed in individual animals following a 10% top load-hypervolemic
infusion protocol (THI), prior to AHET investigations.
During the 40% AHET experimental protocol animals were
randomly assigned to 1 of 2 observation endpoints, 0.5 or 2 hrs
following the infusion of individual plasma expanders: Ringer’s
Lactate (RL; Baxter Healthcare Corporation Deerfield, IL),
Dextran (Dex; 70 kDa molecular weight; B Braun Medical, Inc.
Irvine, CA), 6% Hetastarch (6Ht; 670 kDa average molecular
weight; Hospira, Inc. Lake Forest, IL), or 4% EAF PEG-Alb
(developed at Albert Einstein College of Medicine, Bronx, NY).
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transfusion
Unanesthetized animals were placed in a restraining tube and
given a 30–60 min adjustment period. Baseline measurements
were then taken (MAP, HR, and Hct). The volume of the 40%
AHET was calculated as a percentage of the animal’s total blood
volume, estimated as 6% of body weight. Animals were observed
through their assigned end time points. Upon the conclusion of
observation periods 30 to 50% of the animal’s total blood volume
was collected for cytokine assay. Blood of control animals was
collected following baseline measurements, without having been
exposed to the infusion/transfusion of fluids and the AHET
protocol.
Cytokine Analysis
Whole blood was collected, without anticoagulant from the
arterial catheter. Blood was allowed to clot for 30 min and was
then centrifuged for 10 min at 1000 g. Serum supernatants were
removed immediately, placed in Eppendorf tubes, and stored at
280uC until analyzed. Samples were assayed for 31 analytes
(Eotaxin, G-CSF, GM-CSF, IFN-c, IL-10, IL-12 (p40), IL-12
(p70), IL-13, IL-15, IL-17, IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-
6, IL-7, IP-10, KC, LIF, LIX, M-CSF, MCP-1, MIG, MIP-1a,
MIP-1b, MIP-2, RANTES, TNF-a, and VEGF) using the
MILLIPLEX
TM MAP Mouse Cytokine/Chemokine Panel (Bio-
Marker Services, Millipore, St. Charles, MO).
Blood Viscosity Measurements
Hemodiluted blood viscosity was determined in vitro. Whole
blood collected from donor mice was mixed to the appropriate
60:40 ratio with each of the individual plasma expanders. Viscosity
measurements were performed with a cone/plate viscometer
(model DV-II; Brookfield; Middelboro, MA), CPE-40 cone spindle
at 37uC, and a shear rate of 200 s
21, representative of the
prevalent shear rates found during normal flow states of the
microvasculature [32,33].
Data Analysis
Data analysis was performed using the dChip 2008 (build date
8th May 2008) platform and/or GraphPad Prism version 4
software (La Jolla, CA).
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